

DEWEY BALLANTINE LLP

1301 AVENUE OF THE AMERICAS
NEW YORK 10019-6092
TEL 212 259-8000 FAX 212 259-6333

WAYNE A. CROSS
212 259-6850
wayne_cross@deweyballantine.com

March 30, 2001



Via Email: genericdrugstudy@ftc.gov and First Class Mail

The Federal Trade Commission
Room H-159
600 Pennsylvania Avenue, N.W.
Washington, D.C. 20580

Attention: Secretary

Re: Generic Drug Study – FTC File No. V000014

Ladies and Gentlemen:

As counsel for Novartis Pharmaceuticals Corporation, I respectfully submit the following comment in connection with the Commission's second notice for public comments relating to its proposed generic drug study. To the extent the Commission determines that it will collect information about citizen petitions with respect to ANDA applications, Novartis submits that the Commission should seek similar information from generic manufacturers.

Respectfully yours,



Wayne A. Cross

cc: Office of Information and Regulatory Affairs
Office of Management and Budget
New Executive Office Building, Room 10202
Washington, D.C. 20503
Attention: Desk Officer for the FTC